Innovent Biologics, Inc. (INNOVENT) income statement

HKSE · Healthcare · Biotechnology · 8,754 employees · CEO De-Chao Yu

Price: HK$80.65 +1.13%
Market cap: HK$141B
Enterprise value: CN¥104B
Last report: Q2 '26 filed 2026-06-30
Next report: 2027-03-31

Innovent Biologics, Inc. (INNOVENT) reported revenue of CN¥8.5B for Q2 '26 (+42.8% year on year), operating income of CN¥1.88B (22.1% of revenue) and net income of CN¥1.24B. Over the last two half-years revenue was CN¥15.6B.

Income statement

Income statement	Q4 '20	Q2 '21	Q4 '21	Q2 '22	Q4 '22	Q2 '23	Q4 '23	Q2 '24	Q4 '24	Q2 '25	Q4 '25	Q2 '26
Revenue	CN¥2.86B	CN¥1.94B	CN¥2.33B	CN¥2.24B	CN¥2.32B	CN¥2.7B	CN¥3.5B	CN¥3.95B	CN¥5.47B	CN¥5.95B	CN¥7.09B	CN¥8.5B
Cost of revenue	CN¥452M	CN¥557M	CN¥668M	CN¥708M	CN¥673M	CN¥782M	CN¥1.03B	CN¥1.09B	CN¥1.32B	CN¥1.39B	CN¥1.69B	CN¥1.28B
Gross profit	CN¥2.41B	CN¥1.39B	CN¥1.66B	CN¥1.53B	CN¥1.64B	CN¥1.92B	CN¥2.48B	CN¥2.86B	CN¥4.15B	CN¥4.57B	CN¥5.4B	CN¥7.22B
Research & development	CN¥1.04B	CN¥974M	CN¥1.35B	CN¥1.17B	CN¥1.7B	CN¥923M	CN¥1.3B	CN¥1.4B	CN¥1.28B	CN¥1.01B	CN¥1.62B	CN¥1.66B
Sales & marketing	CN¥894M	CN¥1.08B	CN¥1.54B	CN¥1.4B	CN¥1.19B	CN¥1.35B	CN¥1.75B	CN¥1.88B	CN¥2.47B	CN¥2.38B	CN¥3.34B	CN¥0
General & administrative	CN¥250M	CN¥308M	CN¥498M	CN¥408M	CN¥428M	CN¥368M	CN¥382M	CN¥320M	CN¥418M	CN¥442M	CN¥485M	CN¥0
Operating expenses	CN¥2.74B	CN¥2.36B	CN¥3.41B	CN¥2.49B	CN¥2.95B	CN¥2.13B	CN¥3.44B	CN¥3.6B	CN¥4.17B	CN¥3.83B	CN¥5.44B	CN¥5.34B
Operating income	CN¥220M	-CN¥981M	-CN¥1.72B	-CN¥1.45B	-CN¥1.67B	-CN¥719M	-CN¥960M	-CN¥741M	-CN¥15.2M	CN¥742M	-CN¥8.41M	CN¥1.88B
Interest income	CN¥95.4M	CN¥0	CN¥143M	CN¥0	CN¥132M	CN¥50.3M	CN¥403M	CN¥0	CN¥394M	CN¥129M	CN¥0	CN¥351M
Interest expense	CN¥0	CN¥27.1M	CN¥113M	CN¥44.6M	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥18M	CN¥40.4M
Other non-operating income (gains on investments, FX ...)	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	-CN¥115M	-CN¥308M	CN¥308M	CN¥0	CN¥0	CN¥0
Total non-operating income	-CN¥474M	-CN¥22.1M	CN¥83.7M	CN¥450M	CN¥502M	CN¥463M	CN¥72.2M	CN¥348M	CN¥329M	CN¥155M	-CN¥49.8M	-CN¥292M
Income before tax	-CN¥254M	-CN¥1B	-CN¥1.64B	-CN¥999M	-CN¥1.17B	-CN¥256M	-CN¥888M	-CN¥393M	CN¥314M	CN¥897M	-CN¥58.2M	CN¥1.59B
Income tax	CN¥136M	CN¥152K	CN¥86.9M	-CN¥48.4M	CN¥57.2M	-CN¥117M	CN¥462K	CN¥35K	CN¥16M	CN¥62.8M	-CN¥37.4M	CN¥354M
Net income	-CN¥390M	-CN¥1B	-CN¥1.73B	-CN¥950M	-CN¥1.23B	-CN¥139M	-CN¥889M	-CN¥393M	CN¥298M	CN¥834M	-CN¥20.8M	CN¥1.24B
EPS (basic)	-CN¥0.28	-CN¥0.70	-CN¥1.18	-CN¥0.64	-CN¥0.82	-CN¥0.09	-CN¥0.56	-CN¥0.24	CN¥0.18	CN¥0.49	-CN¥0.01	CN¥0.72
EPS (diluted)	-CN¥0.28	-CN¥0.70	-CN¥1.18	-CN¥0.64	-CN¥0.82	-CN¥0.09	-CN¥0.56	-CN¥0.24	CN¥0.18	CN¥0.49	-CN¥0.01	CN¥0.68
Shares (basic, weighted)	1.37B	1.45B	1.45B	1.46B	1.52B	1.54B	1.58B	1.62B	1.63B	1.69B	1.71B	1.73B
Shares (diluted, weighted)	1.39B	1.45B	1.46B	1.47B	1.52B	1.54B	1.58B	1.62B	1.63B	1.69B	1.79B	1.8B
Depreciation & amortization	CN¥29.3M	CN¥90.6M	CN¥116M	CN¥122M	CN¥199M	CN¥186M	CN¥198M	CN¥199M	CN¥217M	CN¥268M	CN¥336M	CN¥332M
EBITDA	CN¥249M	-CN¥891M	-CN¥1.61B	-CN¥1.33B	-CN¥1.48B	-CN¥533M	-CN¥647M	-CN¥233M	-CN¥107M	CN¥1.01B	CN¥327M	CN¥2.21B

Income statement	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	CN¥32.1M	CN¥18.5M	CN¥9.48M	CN¥1.05B	CN¥3.84B	CN¥4.27B	CN¥4.56B	CN¥6.21B	CN¥9.42B	CN¥13B
Cost of revenue	CN¥0	-CN¥71.5M	-CN¥1.31M	CN¥125M	CN¥388M	CN¥573M	CN¥931M	CN¥1.81B	CN¥1.51B	CN¥3.04B
Gross profit	CN¥32.1M	CN¥90M	CN¥10.8M	CN¥923M	CN¥3.46B	CN¥3.7B	CN¥3.63B	CN¥4.4B	CN¥7.91B	CN¥10B
Research & development	CN¥385M	CN¥612M	CN¥1.22B	CN¥1.29B	CN¥1.85B	CN¥2.48B	CN¥2.87B	CN¥2.23B	CN¥2.68B	CN¥2.62B
Sales & marketing	CN¥0	CN¥8.28M	CN¥136M	CN¥1.19B	CN¥1.34B	CN¥2.62B	CN¥2.59B	CN¥3.1B	CN¥4.35B	CN¥5.71B
General & administrative	CN¥57.4M	CN¥79.5M	CN¥278M	CN¥255M	CN¥437M	CN¥884M	CN¥835M	CN¥750M	CN¥738M	CN¥927M
Other operating expenses	-CN¥123M	-CN¥51M	-CN¥4.34B	-CN¥41.4M	-CN¥131M	-CN¥342M	-CN¥90.2M	CN¥0	-CN¥112M	CN¥0
Operating expenses	CN¥413M	CN¥643M	CN¥1.56B	CN¥2.7B	CN¥3.5B	CN¥5.75B	CN¥6.21B	CN¥6.08B	CN¥7.65B	CN¥9.26B
Operating income	-CN¥462M	-CN¥750M	-CN¥1.79B	-CN¥1.66B	-CN¥557M	-CN¥2.7B	-CN¥3.12B	-CN¥1.68B	-CN¥756M	CN¥734M
Interest income	CN¥4.54M	CN¥7.98M	CN¥20.7M	CN¥103M	CN¥116M	CN¥152M	CN¥190M	CN¥453M	CN¥423M	CN¥427M
Interest expense	CN¥53.8M	CN¥57.2M	CN¥69M	CN¥59.5M	CN¥68.4M	CN¥62.5M	CN¥102M	CN¥98.6M	CN¥67.6M	CN¥77.5M
Other non-operating income (gains on investments, FX ...)	CN¥0	CN¥34.1M	CN¥4.25B	-CN¥2.63M	CN¥0	CN¥0	-CN¥513M	-CN¥634M	CN¥269M	CN¥0
Total non-operating income	-CN¥131M	-CN¥91.3M	-CN¥4.32B	-CN¥56.9M	-CN¥302M	CN¥61.6M	CN¥952M	CN¥535M	-CN¥337M	CN¥105M
Income before tax	-CN¥544M	-CN¥716M	-CN¥5.87B	-CN¥1.72B	-CN¥859M	-CN¥2.64B	-CN¥2.17B	-CN¥1.14B	-CN¥78.6M	CN¥839M
Income tax	-CN¥151M	-CN¥244M	CN¥27.5M	CN¥56.9M	CN¥140M	CN¥87M	CN¥8.8M	-CN¥116M	CN¥16M	CN¥25.4M
Net income	-CN¥504M	-CN¥562M	-CN¥5.77B	-CN¥1.72B	-CN¥998M	-CN¥2.73B	-CN¥2.18B	-CN¥1.03B	-CN¥94.6M	CN¥814M
EPS (basic)	-CN¥0.45	-CN¥0.50	-CN¥17.24	-CN¥1.51	-CN¥0.74	-CN¥1.88	-CN¥1.46	-CN¥0.66	-CN¥0.06	CN¥0.48
EPS (diluted)	-CN¥0.45	-CN¥0.50	-CN¥17.24	-CN¥1.51	-CN¥0.74	-CN¥1.88	-CN¥1.46	-CN¥0.66	-CN¥0.06	CN¥0.47
Shares (basic, weighted)	1.12B	1.12B	335M	1.18B	1.35B	1.45B	1.49B	1.56B	1.63B	1.73B
Shares (diluted, weighted)	1.12B	1.12B	335M	1.18B	1.36B	1.46B	1.49B	1.56B	1.63B	1.74B
Depreciation & amortization	CN¥54.6M	CN¥61.1M	CN¥64.1M	CN¥86.4M	CN¥85.6M	CN¥205M	CN¥319M	CN¥385M	CN¥420M	CN¥601M
EBITDA	-CN¥359M	-CN¥598M	-CN¥5.74B	-CN¥1.57B	-CN¥705M	-CN¥2.37B	-CN¥1.75B	-CN¥661M	-CN¥336M	CN¥1.33B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.